This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Conjuchem Biotechnologies Inc.. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Innovations of Jun Liang in HIV Research
Introduction
Jun Liang is an accomplished inventor based in Boyds, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of antiviral therapies. His work focuses on creating innovative solutions to combat viral infections, including HIV.
Latest Patents
Jun Liang holds a patent for "Long lasting fusion peptide inhibitors for HIV infection." This invention relates to C34 peptide derivatives that act as inhibitors of viral infection and exhibit antifusogenic properties. Specifically, the patent addresses C34 derivatives that have inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV). The invention is notable for its long duration of action, making it a promising treatment option for these viral infections. Jun Liang has 1 patent to his name.
Career Highlights
Jun Liang is currently associated with Conjuchem Biotechnologies Inc., where he continues to advance his research in antiviral therapies. His work has the potential to significantly impact public health by providing new treatment options for viral infections.
Collaborations
Jun Liang collaborates with notable colleagues, including John W Erickson and Dominique P Bridon. These partnerships enhance the research and development efforts within his field.
Conclusion
Jun Liang's innovative work in developing long-lasting fusion peptide inhibitors represents a significant advancement in the fight against viral infections, particularly HIV. His contributions to biotechnology are paving the way for new therapeutic options that could improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile